Apicore US LLC v. Beloteca Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Apicore US LLC (Delaware) and Mylan Institutional LLC (Delaware)
  • Defendant: Beloteca, Inc. (California)
  • Plaintiff’s Counsel: Gillam & Smith LLP; Wilson Sonsini Goodrich & Rosati
• Case Identification: 2:19-cv-00077, E.D. Tex., 03/04/2019
• Venue Allegations: Plaintiffs allege venue is proper in the Eastern District of Texas because Defendant has taken significant steps to market its accused product nationwide, including in Texas, and because the suit relates to Defendant’s planned in-state commercial activity.
• Core Dispute: Plaintiffs seek a declaratory judgment that Defendant's planned manufacture and sale of a generic isosulfan blue injectable drug product, subject of an approved Abbreviated New Drug Application (ANDA), will infringe two patents covering a process for making high-purity isosulfan blue and the resulting high-purity product itself.
• Technical Context: The technology concerns chemical synthesis processes for producing isosulfan blue, a triarylmethane dye used as a contrast agent for delineating lymphatic vessels, particularly in cancer-related procedures.
• Key Procedural History: The complaint notes that the day after its ANDA was approved, Defendant Beloteca filed its own declaratory judgment action for non-infringement and invalidity in the Northern District of Illinois. The complaint also references a pending Inter Partes Review (IPR) proceeding (IPR2018-01640) against the ’050 patent, initiated by a third party. Finally, Plaintiffs allege a previous case in the E.D. Tex. involving these same patents progressed through a preliminary injunction stage.

Case Timeline

Date	Event
2007-05-11	Priority Date for ’616 and ’050 Patents
2015-03-03	’616 Patent Issued
2016-05-31	’050 Patent Issued
2019-01-16	Beloteca's ANDA No. 210714 Approved
2019-03-04	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,969,616 - Process for Preparation of Isosulfan Blue, issued March 3, 2015

The Invention Explained

• Problem Addressed: The patent’s background section states that prior art methods for synthesizing triarylmethane dyes like isosulfan blue were ill-suited for pharmaceutical applications, often involving harsh acids, hazardous oxidizing agents, and crude purification techniques that resulted in an impure final product (’616 Patent, col. 2:1-12).
• The Patented Solution: The invention provides a multi-step process designed to produce isosulfan blue in a "substantially pure form," defined as 99.0% or greater (’616 Patent, col. 2:30-34). The process involves creating an intermediate compound called "isoleuco acid," which is then converted to isosulfan blue using a mild oxidizing agent (silver oxide) and subjected to specific purification and isolation procedures to achieve high purity suitable for pharmaceutical use (’616 Patent, Abstract; col. 6:58-65).
• Technical Importance: The described process enabled the large-scale, cGMP-compliant manufacturing of a pharmaceutical-grade active ingredient that was previously difficult to produce with high purity (’616 Patent, col. 2:21-25).

Key Claims at a Glance

• The complaint asserts at least independent Claim 1 (Compl. ¶36).
• Claim 1 recites a process with three primary steps:
  • combining a suspension of isoleuco acid of a specific formula in a polar solvent with silver oxide
  • recovering isosulfan blue acid
  • treating the isosulfan blue acid with a sodium solution
• The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 9,353,050 - Process for Preparation of Isosulfan Blue, issued May 31, 2016

The Invention Explained

• Problem Addressed: The ’050 patent shares its specification with the ’616 patent and thus addresses the same problem: the need for a reliable method to produce pharmaceutical-grade isosulfan blue (’050 Patent, col. 2:1-12).
• The Patented Solution: While the ’616 patent claims the process, the ’050 patent claims the end product itself, defined by its chemical structure and, critically, by its level of purity. The invention is the compound, N-[4-[4-(diethyl amino)phenylmethylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium, sodium salt, when it has a purity of at least 99.0% as measured by High Performance Liquid Chromatography (HPLC) (’050 Patent, col. 10:55-61). The patent describes purification procedures to achieve this level of purity (’050 Patent, col. 6:55-60).
• Technical Importance: By claiming the high-purity compound itself, the patent provides protection for the output of the novel manufacturing process, regardless of minor variations in how that process might be executed (’050 Patent, col. 2:21-25).

Key Claims at a Glance

• The complaint asserts at least independent Claim 1 (Compl. ¶50).
• Claim 1 recites a compound with two key limitations:
  • The specific chemical structure for isosulfan blue sodium salt
  • "having a purity of at least 99.0% by HPLC"
• The complaint does not explicitly reserve the right to assert dependent claims.

III. The Accused Instrumentality

• Product Identification: The accused instrumentalities are the "Beloteca ANDA Product," an isosulfan blue for injection product subject to ANDA No. 210714, and the process used to manufacture it (Compl. ¶¶ 2, 4).
• Functionality and Market Context: The complaint alleges that the process for manufacturing the Beloteca ANDA Product is described in Beloteca’s published PCT application, WO2017218764A1 ("the '764 Publication") (Compl. ¶37). The final product is a generic version of the injectable dye commercialized by Plaintiffs (Compl. ¶¶ 8, 20). The complaint asserts that Plaintiffs' product is the FDA-designated "Reference Standard," meaning any generic applicant like Beloteca must demonstrate bioequivalence to it for approval (Compl. ¶¶ 24, 55). No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

’616 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A process of preparing... sodium salt comprising combining a suspension of isoleuco acid... in a polar solvent with silver oxide...	The complaint alleges Beloteca's process, as described in its '764 Publication, includes combining isoleuco acid with silver oxide.	¶39	col. 8:62-65
recovering isosulfan blue acid...	The complaint alleges the '764 Publication discloses a step of recovering isosulfan blue acid.	¶39	col. 9:19-20
and treating the isosulfan blue acid with a sodium solution.	The complaint alleges that the '764 Publication's disclosure of treating the acid with a "sodium ion exchange resin in water" constitutes treating it with a "sodium solution" as claimed.	¶¶40-42	col. 9:22-30

• Identified Points of Contention:
  • Scope Questions: A primary dispute may concern the meaning of "sodium solution." The complaint's theory requires this term to be broad enough to read on the use of a "sodium ion exchange resin in water" (Compl. ¶¶ 41-42). The question for the court will be whether this phrase covers only pre-mixed solutions or also includes processes that form a solution in situ.
  • Technical Questions: The infringement theory relies on the assumption that the process described in Beloteca's published PCT application is the same process Beloteca will use for commercial manufacture under its ANDA (Compl. ¶37). A key factual question will be whether the confidential process details in the ANDA filing match the public disclosure in the '764 Publication.

’050 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A compound N-[4-[4-(diethyl amino)phenylmethylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium, sodium salt...	The Beloteca ANDA Product is alleged to be the claimed isosulfan blue compound.	¶¶2, 50	col. 2:26-29
having a purity of at least 99.0% by HPLC.	The complaint alleges the Beloteca ANDA product has the claimed purity, inferring this from the regulatory requirement that it be bioequivalent to Plaintiffs' own 99% pure product, which serves as the FDA Reference Standard.	¶¶56-59	col. 2:32-34

• Identified Points of Contention:
  • Technical Questions: The core of the infringement allegation for the ’050 patent is an inference. The complaint alleges the accused product is "likely to have the same purity" as Plaintiffs' product because of FDA bioequivalence requirements (Compl. ¶¶ 57-58). A central evidentiary question will be whether Plaintiffs can produce direct evidence that the accused product actually meets the "at least 99.0% by HPLC" purity limitation, or if Beloteca can demonstrate that bioequivalence can be achieved without meeting this specific purity threshold.

V. Key Claim Terms for Construction

• The Term: "sodium solution" (’616 Patent, Claim 1)

  • Context and Importance: The infringement case for the process patent hinges on this term. Beloteca allegedly uses a "sodium ion exchange resin in water," and Plaintiffs allege this meets the "sodium solution" limitation (Compl. ¶¶ 41-42). The viability of the infringement claim depends on whether this interpretation holds.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification does not appear to explicitly define "sodium solution." A party could argue that its plain and ordinary meaning would encompass any method that results in sodium ions being solvated in water to treat the isosulfan blue acid, including through an ion exchange resin.
    • Evidence for a Narrower Interpretation: An exemplary embodiment in the specification describes preparing the sodium salt by adding a "saturated sodium bicarbonate solution" to the isosulfan blue acid (’616 Patent, col. 9:24-26). A party could argue this specific example limits the term to pre-mixed, dissolved salt solutions and excludes solid-phase resins.

• The Term: "purity of at least 99.0% by HPLC" (’050 Patent, Claim 1)

  • Context and Importance: This term is the dispositive limitation for infringement of the ’050 patent. The entire dispute turns on whether the accused product meets this quantitative threshold.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The term itself is facially straightforward. The specification consistently links the invention to high purity, defining "substantially pure" as "99.0% or greater" (’050 Patent, col. 2:32-34). This suggests the number is a clear floor.
    • Evidence for a Narrower Interpretation: It is unlikely a party could argue for a narrower interpretation of "at least 99.0%." Instead, a defendant would likely focus on the factual question of whether its product meets the threshold and may challenge the specific HPLC methodology used to measure it, though the complaint does not provide a basis to analyze this yet.

VI. Other Allegations

• Indirect Infringement: The prayer for relief seeks a judgment of contributory and induced infringement (Compl. p. 9, ¶(e)). The complaint body does not, however, allege specific facts to support these claims, such as instructions or components provided by Beloteca to a third party to perform an infringing act.
• Willful Infringement: The complaint alleges that Beloteca had knowledge of the ’616 and ’050 patents as early as their respective issue dates (Compl. ¶¶ 43-44, 61-62). It further makes the pointed allegation that "Beloteca copied portions of the shared specification of Apicore’s ’616 and ’050 Patents when drafting its ’764 Publication," a reference to Beloteca's own patent application (Compl. ¶46). These allegations of pre-suit knowledge and deliberate copying form the basis for the willfulness claim.

VII. Analyst’s Conclusion: Key Questions for the Case

1. A central issue will be one of claim scope and technical interpretation: For the ’616 process patent, can the claim term "sodium solution" be construed to cover Beloteca's alleged use of a "sodium ion exchange resin in water," or is there a dispositive difference between a pre-mixed solution and an in-situ ion exchange process?

2. The case for the ’050 product patent will turn on a key evidentiary question: Can Plaintiffs move beyond the inference drawn from FDA bioequivalence rules to provide direct, factual proof that Beloteca's generic drug product actually possesses a "purity of at least 99.0% by HPLC" as required by the claim?

3. The litigation will be heavily influenced by parallel proceedings: With a competing declaratory judgment action in another district and a pending IPR on the ’050 patent, a threshold question will be which forum proceeds first and whether the court will stay this case pending the outcome of the PTAB review, potentially narrowing the scope of the dispute before discovery begins.